Aclaris Therapeutics, Inc. (ACRS)
NASDAQ: ACRS · Real-Time Price · USD
2.720
-0.050 (-1.81%)
At close: Dec 20, 2024, 4:00 PM
3.000
+0.280 (10.29%)
After-hours: Dec 20, 2024, 7:05 PM EST
Aclaris Therapeutics Employees
As of December 31, 2023, Aclaris Therapeutics had 91 total employees, including 86 full-time and 5 part-time employees. The number of employees decreased by 14 or -13.33% compared to the previous year.
Employees
91
Change (1Y)
-14
Growth (1Y)
-13.33%
Revenue / Employee
$297,571
Profits / Employee
-$406,637
Market Cap
291.00M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Canopy Growth | 1,029 |
Cerus | 637 |
CVRx, Inc. | 200 |
Rigel Pharmaceuticals | 147 |
Nyxoah | 147 |
Silence Therapeutics | 109 |
enGene Holdings | 33 |
Immutep | 31 |
ACRS News
- 18 days ago - Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 25 days ago - Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference - GlobeNewsWire
- 4 weeks ago - Aclaris Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments - Benzinga
- 4 weeks ago - Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets - PRNewsWire
- 4 weeks ago - Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline - GlobeNewsWire
- 4 weeks ago - Aclaris Therapeutics Announces $80 Million Private Placement - GlobeNewsWire
- 3 months ago - Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis - GlobeNewsWire
- 3 months ago - Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference - GlobeNewsWire